Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
Speaker 1: your roundup of companies making moves in the stock market,
Speaker 1: harnessing the power of Bloomberg Data. Stockmovers is John Tucker's
Speaker 1: a podcast. John decided to start out where I am John?
Speaker 2: Did my body Mass Index this weekend? Yeah?
Speaker 1: Came over did my BMI?
Speaker 2: As they say, he said with Govy Novo nordis good
Speaker 2: luck with that. Yeah, I mean I know a lot
Speaker 2: of people who take it, but the side effects it
Speaker 2: just you know, can vary from individual to individual. Now
Speaker 2: there's apparently a new use for it. Novo shares advancing
Speaker 2: after the drugmaker's blockbuster weight loss drug WEGV has now
Speaker 2: received US approval to treat a serious form of liver disease.
Speaker 2: The important part of this also is that they beat
Speaker 2: one of their competitors, Eli Lilly to the US market,
Speaker 2: So this particular approval gives Novo a big win in
Speaker 2: the booming market for the GLP one drugs they of course,
Speaker 2: have been popularized for weight loss. The drug makers started
Speaker 2: the year as Europe's most valuable traded company, but it's
Speaker 2: since lost about half of its value as it wrestles
Speaker 2: with fierce competition in the obesity market. So the liver
Speaker 2: clearance marks the second boost for Nova this month, after
Speaker 2: disappointing data from Lily's obesity bill boosted investor hopes about
Speaker 2: Novo's ability to Competegovie was clear for a disease known
Speaker 2: as mash in adults with moderate to advance scar tissue
Speaker 2: in the liver. A mash develops when fat builds up
Speaker 2: in the liver, causing inflammation and potentially leading to more
Speaker 2: serious conditions like cirrhosis and cancer. So Wgovie helps reverse
Speaker 2: the damage to the liver, according to Novo nord Disk. Next,
Speaker 2: let's go to a company called day Force, the ticker
Speaker 2: symbol day so human resources management software provider. It is
Speaker 2: the target of Tomo Bravo, the buyout firm planning to
Speaker 2: take the Minneapolis based company private. This is a deal
Speaker 2: that could be announced as soon as the coming weeks.
Speaker 2: Day four shares they have fallen about the sixty percent
Speaker 2: from their twenty twenty one peak, while the company increased
Speaker 2: revenue more than seventy percent between twenty twenty one and
Speaker 2: twenty twenty four and became more profitable again. This is
Speaker 2: the enterprise software market. They make human resources software. This
Speaker 2: market has had difficulties maintaining momentum after a run up
Speaker 2: during the COVID nineteen lockdowns, and let's wrap up with
Speaker 2: this one. We constantly asked the question Apple, where's its
Speaker 2: mojo going? An interesting take from Mark German. He focuses
Speaker 2: on Apple's Vision Pro headset. It isn't selling well for
Speaker 2: a couple of reasons. First of all, it's thirty five
Speaker 2: hundred dollars price sag, and then there's the lack of
Speaker 2: sufficiently compelling features. There are other issues like a limited
Speaker 2: array of custom applications and the device's weight and cumbersome
Speaker 2: setup process. By all accounts, the device remains an extremely
Speaker 2: niche product. Moreover, the headset doesn't feel like a priority
Speaker 2: for Apple. On the the last earnings call, for instance,
Speaker 2: Tim Cook almost seems surprised when a Wallstreet analyst quiz
Speaker 2: him about the device and also the company's strategy. So
Speaker 2: there you go. Mark Dermott strikes again on it.
Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
Speaker 1: us throughout the day for the latest roundup of companies
Speaker 1: making news on Wall Street and for the latest market
Speaker 1: moving headlines. Listen to Bloomberg Radio Live. Catch us on YouTube,
Speaker 1: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 1: the Bloomberg Business appe